Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Marketing Status Prescription; Discontinued
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 70436-012; 70436-013; 50090-4806; 0054-0401; 46708-152; 70518-3195; 68382-469; 0591-3659; 71335-1815; 0054-0603; 70436-036; 71335-1753; 51407-023; 0591-4060; 50090-4388; 63304-191; 0591-3660; 14501-0068; 46708-153; 60687-607; 70771-1311; 68382-741; 71335-1975; 0054-0400; 51407-022; 63304-192; 63629-7524; 71335-1700; 70771-1312; 69766-025
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mood altered19.04.02.0070.003384%Not Available
Mood swings19.04.03.0010.001692%Not Available
Movement disorder17.01.02.0100.000846%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.000846%Not Available
Muscle spasms15.05.03.0040.003384%
Muscle twitching15.05.03.0050.002115%Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.0040.002115%Not Available
Myocardial infarction02.02.02.007; 24.04.04.009--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Narcolepsy19.02.02.002; 17.15.01.0020.000846%Not Available
Nasal congestion22.04.04.0010.000846%
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.0010.026648%
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.0030.005922%Not Available
Nightmare19.02.03.0030.003807%Not Available
Obesity14.03.02.0090.002115%
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.011--
Oral discomfort07.05.05.0010.000846%Not Available
Orgasm abnormal21.03.02.013; 19.08.01.004--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Osteoarthritis15.01.04.0010.000846%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pain in jaw15.02.01.0030.001269%Not Available
Palpitations02.01.02.0030.003807%
Pancreatitis07.18.01.0010.001269%
Pancreatitis acute07.18.01.002--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages